Virchows Archiv

, Volume 474, Issue 4, pp 497–509 | Cite as

Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy

  • Thomas Menter
  • Alexandar TzankovEmail author
Review Article


Chromosome 9 harbors several relevant oncogenes related to hematolymphoid malignancies and one specific region, 9p24, has come into the focus of attention in the last years as it contains recurrently mutant genes of therapeutic interest. The most prominent genes of this locus are programmed death ligands 1 and 2 (PDL1/PDL2), with the amplification of PDL1 being a hallmark of both classical Hodgkin and primary mediastinal B cell lymphoma, and Janus kinase 2 (JAK2), which is point-mutated in myeloproliferative neoplasms and other myeloid malignancies, and rearranged in PCM1-JAK2-positive myeloid/lymphoid neoplasms with eosinophila. Finally, this locus contains the lysine (K)-specific demethylase 4C (KDM4C/JMJD2C), which is also relevant for oncogenesis. Activation of these genes is effectuated, as exemplified, by multiple mechanisms, which is rather unique to oncogenes, since they are usually affected by just one type of mutation, and points towards the central role of these genes in tumor initiation and growth. Amplifications and, less frequently, translocations are the most common findings for PDL1/PDL2 and JAK2 in lymphomas. In this review, we describe the role of genes located on chromosome 9p24 and their derived proteins in diverse subtypes of lymphomas, with a special focus on PDL1 and PDL2, which are becoming a central target of immunotherapy, not only in classical Hodgkin lymphoma but also in various types of solid cancers. We also elucidate the role of the surgical pathologists in this setting — concerning what they can contribute — both diagnostically and predictively.


Chromosome 9p24 PDL1 PDL2 JAK2 Lymphoma 



Both authors conceived and wrote the manuscript. Both authors gave final approval for publication. AT takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
  2. 2.
    Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S et al (2004) DNA sequence and analysis of human chromosome 9. Nature 429(6990):369–374. Google Scholar
  3. 3.
    Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang ZY, Edidin MA, Nathenson SG, Almo SC (2004) Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20(3):337–347Google Scholar
  4. 4.
    Kota J, Caceres N, Constantinescu SN (2008) Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22(10):1828–1840. Google Scholar
  5. 5.
    Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A (2011) PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 15(1):53–62. Google Scholar
  6. 6.
    Heiss S, Erdel M, Gunsilius E, Nachbaur D, Tzankov A (2005) Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 36(10):1148–1151. Google Scholar
  7. 7.
    Bain BJ, Horny H-P, Arber DA, Tefferi A, Hasserjian RP (2017) Myeloid/lymphoid neoplasms with eosinophilia and rearrrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, LyonGoogle Scholar
  8. 8.
    Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I (2011) JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 117(15):4056–4064. Google Scholar
  9. 9.
    Van Roosbroeck K, Ferreiro JF, Tousseyn T, van der Krogt JA, Michaux L, Pienkowska-Grela B, Theate I, De Paepe P, Dierickx D, Doyen C, Put N, Cools J, Vandenberghe P, Wlodarska I (2016) Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes Cancer 55(5):428–441. Google Scholar
  10. 10.
    Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277. Google Scholar
  11. 11.
    Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A (2017) Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. J Hematol Oncol 10(1):70. Google Scholar
  12. 12.
    Berry WL, Janknecht R (2013) KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73(10):2936–2942. Google Scholar
  13. 13.
    Pardoll D (2015) Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol 42(4):523–538. Google Scholar
  14. 14.
    Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL (2015) Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 42(4):587–600. Google Scholar
  15. 15.
    Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. Google Scholar
  16. 16.
    Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 22(3):476–487. Google Scholar
  17. 17.
    Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P et al (2010) Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18(6):590–605. Google Scholar
  18. 18.
    Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, Fang W, Wang X, Meng B, Zhang L, Zeng Y, Bhagat G, Nordenskjold M, Sundstrom C, Enblad G, Dalla-Favera R, Zhang H, Teixeira MR, Pasqualucci L, Peng R, Pan-Hammarstrom Q (2016) Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 127(24):3026–3034. Google Scholar
  19. 19.
    Panagopoulos I, Gorunova L, Spetalen S, Bassarova A, Beiske K, Micci F, Heim S (2017) Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma. Oncotarget 8(61):103775–103784. Google Scholar
  20. 20.
    Bain BJ, Ahmad S (2014) Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166(6):809–817. Google Scholar
  21. 21.
    Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B (2008) Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 14(20):6426–6431. Google Scholar
  22. 22.
    Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C, Imbert M, Chaffanet M, Birnbaum D, Mozziconacci MJ (2006) A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20(3):536–537. Google Scholar
  23. 23.
    Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005–1015. Google Scholar
  24. 24.
    Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65(7):2662–2667. Google Scholar
  25. 25.
    Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534(7607):402–406. Google Scholar
  26. 26.
    Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C (2015) Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol 236(2):136–141. Google Scholar
  27. 27.
    Juskevicius D, Jucker D, Dietsche T, Perrina V, Rufle A, Ruiz C, Dirnhofer S, Tzankov A (2018) Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues. Lab Invest.
  28. 28.
    Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A (2016) Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol 54:17–24. Google Scholar
  29. 29.
    Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, Ruschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29(10):1165–1172. Google Scholar
  30. 30.
    Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR (2016) The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 91(10):E436–E441. Google Scholar
  31. 31.
    Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690–2697. Google Scholar
  32. 32.
    Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895Google Scholar
  33. 33.
    Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369. Google Scholar
  34. 34.
    Messal N, Serriari NE, Pastor S, Nunes JA, Olive D (2011) PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 48(15–16):2214–2219. Google Scholar
  35. 35.
    Muenst S, Soysal SD, Tzankov A, Hoeller S (2015) The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 19(2):201–211. Google Scholar
  36. 36.
    Menter T, Tzankov A (2018) Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol 8:54. Google Scholar
  37. 37.
    Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015–3029. Google Scholar
  38. 38.
    Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541–547Google Scholar
  39. 39.
    Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319–322. Google Scholar
  40. 40.
    Ok CY, Young KH (2017) Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 10(1):103. Google Scholar
  41. 41.
    Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123(13):2062–2065. Google Scholar
  42. 42.
    Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127(7):869–881. Google Scholar
  43. 43.
    Choi JW, Kim Y, Lee JH, Kim YS (2013) MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 44(7):1375–1381. Google Scholar
  44. 44.
    Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611–1618. Google Scholar
  45. 45.
    Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ, Wang L (2016) PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 9(1):109. Google Scholar
  46. 46.
    Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 105(52):20852–20857. Google Scholar
  47. 47.
    Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A (2017) Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 108(4):574–580. Google Scholar
  48. 48.
    Gascoyne RD, Rosenwald A, Poppema S, Lenz G (2010) Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 51(Suppl 1):11–19. Google Scholar
  49. 49.
    Carbone A, Gloghini A (2013) Relationships between lymphomas linked to hepatitis C virus infection and their microenvironment. World J Gastroenterol 19(44):7874–7879. Google Scholar
  50. 50.
    Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462–3473. Google Scholar
  51. 51.
    Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193–2201. Google Scholar
  52. 52.
    Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S (2013) The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98(6):953–963. Google Scholar
  53. 53.
    Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A (2010) Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 29(1):47–53. Google Scholar
  54. 54.
    Muenst S, Hoeller S, Dirnhofer S, Tzankov A (2009) Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 40(12):1715–1722. Google Scholar
  55. 55.
    Goodman A, Patel SP, Kurzrock R (2017) PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 14(4):203–220. Google Scholar
  56. 56.
    Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ (2014) Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 38(12):1715–1723. Google Scholar
  57. 57.
    Wang Y, Wu L, Tian C, Zhang Y (2018) PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann Hematol 97(2):229–237. Google Scholar
  58. 58.
    Merryman RW, Armand P, Wright KT, Rodig SJ (2017) Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv 1(26):2643–2654. Google Scholar
  59. 59.
    Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311–319. Google Scholar
  60. 60.
    Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733–3739. Google Scholar
  61. 61.
    Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, Keynote (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132. Google Scholar
  62. 62.
    Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH (2017) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183–1194. Google Scholar
  63. 63.
    Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21(1):15–25. Google Scholar
  64. 64.
    Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P (2017) Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130(3):267–270. Google Scholar
  65. 65.
    Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34(23):2698–2704. Google Scholar
  66. 66.
    Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69–77. Google Scholar
  67. 67.
    Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA (2017) PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129(23):3071–3073. Google Scholar
  68. 68.
    Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL (2017) PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97:193–196. Google Scholar
  69. 69.
    Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ (2016) PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 7(37):59976–59986. Google Scholar
  70. 70.
    Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, Veloso Y, Dizdarevic A, Gatalica Z (2016) PD-L1 status in refractory lymphomas. PLoS One 11(11):e0166266. Google Scholar
  71. 71.
    Mino-Kenudson M (2017) Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Transl Lung Cancer Res 6(5):570–587. Google Scholar
  72. 72.
    Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol.
  73. 73.
    Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX (2006) JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 38(9):1071–1076. Google Scholar
  74. 74.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790. Google Scholar
  75. 75.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459–468. Google Scholar
  76. 76.
    Scott LM (2013) Lymphoid malignancies: another face to the Janus kinases. Blood Rev 27(2):63–70. Google Scholar
  77. 77.
    Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL (2009) No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma. Diagn Mol Pathol 18(3):144–149. Google Scholar
  78. 78.
    Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T (2009) Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 113(12):2746–2754. Google Scholar
  79. 79.
    Ehrentraut S, Nagel S, Scherr ME, Schneider B, Quentmeier H, Geffers R, Kaufmann M, Meyer C, Prochorec-Sobieszek M, Ketterling RP, Knudson RA, Feldman AL, Kadin ME, Drexler HG, MacLeod RA (2013) T(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. PLoS One 8(1):e53767. Google Scholar
  80. 80.
    Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M et al (2018) Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10(429):eaam7729. Google Scholar
  81. 81.
    Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A (2007) Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110(9):3387–3390. Google Scholar
  82. 82.
    Mottok A, Renne C, Seifert M, Oppermann E, Bechstein W, Hansmann ML, Kuppers R, Brauninger A (2009) Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 114(20):4503–4506. Google Scholar
  83. 83.
    Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, Ben-Neriah S, Mottok A, Lim RS, Boyle M, Rogic S, Rimsza LM, Guiter C, Leroy K, Gaulard P, Haioun C, Marra MA, Savage KJ, Connors JM, Shah SP, Gascoyne RD, Steidl C (2014) Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 46(4):329–335. Google Scholar
  84. 84.
    Couronne L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, Vainchenker W, Merlio JP, Beylot-Barry M, Damm F, Stern MH, Gaulard P, Lamant L, Delabesse E, Merle-Beral H, Nguyen-Khac F, Fontenay M, Tilly H, Bastard C, Zucman-Rossi J, Bernard OA, Mercher T (2013) STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 98(11):1748–1752. Google Scholar
  85. 85.
    Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Moller P, Leroy K (2009) Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 114(6):1236–1242. Google Scholar
  86. 86.
    Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115–119. Google Scholar
  87. 87.
    Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM (2014) A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123(9):1293–1296. Google Scholar
  88. 88.
    Roncero AM, Lopez-Nieva P, Cobos-Fernandez MA, Villa-Morales M, Gonzalez-Sanchez L, Lopez-Lorenzo JL, Llamas P, Ayuso C, Rodriguez-Pinilla SM, Arriba MC, Piris MA, Fernandez-Navarro P, Fernandez AF, Fraga MF, Santos J, Fernandez-Piqueras J (2016) Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia 30(1):94–103. Google Scholar
  89. 89.
    Gerlach MM, Arranto C, Dirnhofer S, Tzankov A (2018) Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values. Ann Hematol.
  90. 90.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31(2):233–239. Google Scholar
  91. 91.
    Van den Neste E, Andre M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Guesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F (2018) Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica 103:840–848. Google Scholar
  92. 92.
    Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. Google Scholar
  93. 93.
    Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K (2006) The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442(7100):307–311. Google Scholar
  94. 94.
    Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298–303. Google Scholar
  95. 95.
    Min DJ, Licht JD (2010) Partners in crime: genes within an amplicon collude to globally deregulate chromatin in lymphoma. Cancer Cell 18(6):539–541. Google Scholar
  96. 96.
    Kuhnl A, Cunningham D, Chau I (2017) Beyond genomics - targeting the epigenome in diffuse large B-cell lymphoma. Cancer Treat Rev 59:132–137. Google Scholar
  97. 97.
    Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, Sing WP, Tam J, Thirugananam A, Noghabi MS, Pang YH, Ang HS, Mitchell W, Robson P, Kaldis P, Soo RA, Swarup S, Lim EH, Lim B (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148(1–2):259–272. Google Scholar
  98. 98.
    Li X, Cui C, Guo Y, Yang G (2015) Glycine decarboxylase expression increased in p53-mutated B cell lymphoma mice. Oncol Res Treat 38(11):586–589. Google Scholar
  99. 99.
    Zhang MS, Arnaoutov A, Dasso M (2014) RanBP1 governs spindle assembly by defining mitotic ran-GTP production. Dev Cell 31(4):393–404. Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Pathology and Medical GeneticsUniversity of Basel and University Hospital BaselBaselSwitzerland

Personalised recommendations